Seralutinib

Overview

Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. Seralutinib also targets to CSF1R and c-KIT with IC 50 s of 8 nM and 14 nM, respectively. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension.

Application

Products | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > PDGFR | Products > Signaling Pathways > c-Fms | Products > Signaling Pathways > c-Kit

Product Information

• Catalog No.: HY-109190
• CAS No.: 1619931-27-9
• Molecular Formula: C27H27N5O3
• Molecular Weight: 469.53
• Purity: 99.94%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 5.75 mg/mL (12.25 mM); Clear solution
• Availability: In-stock

Source

Original product source